title: Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
abstract: The objective of this study was to investigate the efficacy of first-line chemotherapy containing irinotecan and/or oxaliplatin in patients with advanced mucinous colorectal cancer. Prognostic factors associated with response rate and survival were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The population included 255 patients, of whom 49 (19%) had mucinous and 206 (81%) had non-mucinous colorectal cancer. The overall response rates for mucinous and non-mucinous tumours were 18.4 (95% CI, 7.5-29.2%) and 49% (95% CI, 42.2-55.8%), respectively (P=0.0002). After a median follow-up of 45 months, median overall survival for the mucinous patients was 14.0 months compared with 23.4 months for the non-mucinous group (hazard ratio (HR), 1.74; CI 95%, 1.27-3.31; P=0.0034). After adjustment for significant features by multivariate Cox regression analysis, mucinous histology was associated with poor overall survival (HR, 1.593, 95% CI, 1.05-2.40; P=0.0267), together with performance status ECOG 2, number of metastatic sites > or =2, and peritoneal metastases. This retrospective analysis shows that patients with mucinous colorectal cancer have poor responsiveness to oxaliplatin/irinotecan-based first-line combination chemotherapy and an unfavourable prognosis compared with non-mucinous colorectal cancer patients.
authors.affiliation: Medical Oncology, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy. catalano_v@yahoo.it
authors.forename: V
authors.initials: V
authors.lastname: Catalano
authors.forename: F
authors.initials: F
authors.lastname: Loupakis
authors.forename: F
authors.initials: F
authors.lastname: Graziano
authors.forename: U
authors.initials: U
authors.lastname: Torresi
authors.forename: R
authors.initials: R
authors.lastname: Bisonni
authors.forename: D
authors.initials: D
authors.lastname: Mari
authors.forename: L
authors.initials: L
authors.lastname: Fornaro
authors.forename: A M
authors.initials: AM
authors.lastname: Baldelli
authors.forename: P
authors.initials: P
authors.lastname: Giordani
authors.forename: D
authors.initials: D
authors.lastname: Rossi
authors.forename: P
authors.initials: P
authors.lastname: Alessandroni
authors.forename: L
authors.initials: L
authors.lastname: Giustini
authors.forename: R R
authors.initials: RR
authors.lastname: Silva
authors.forename: A
authors.initials: A
authors.lastname: Falcone
authors.forename: S
authors.initials: S
authors.lastname: D'Emidio
authors.forename: S L
authors.initials: SL
authors.lastname: Fedeli
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D053842:Microsatellite Instability; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002166:Camptothecin